Skip to main content

Nektar Therapeutics

NKTR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000906709

In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 242 institutions reported holding it in 13F filings for Q3 2026, worth $2.17B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$1.11B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $22.3K in total
2
13F holdersQ3 2026, +5 vs. previous quarter
242
13F valueReported value at the end of Q3 2026
$2.17B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$55.2M
−43.9% year over year
Net income, FY2025
-$164.1M
No comparable prior period
Free cash flow, FY2025
-$208.7M
No comparable prior period
Revenue, Q3 FY2026
$9.39M
−20.4% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $164.1M (297.1% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
6.77M
Shares sold short
Change
−231.7K
−3.3% vs. previous
Days to cover
10.26
At average daily volume

Superinvestors holding NKTR, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding NKTR at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Nektar Therapeutics insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 19, 2026 (view filing)6:50 PM ETNov 172 daysRobin Howard WPresident & CEOSSale−429$35.85−$15.4K−0.8%54.2K after
Nov 19, 2026 (view filing)6:50 PM ETNov 172 daysZalevsky JonathanChief R&D OfficerSSale−192$35.85−$6.88K−2.0%9.38K after
Aug 20, 2026 (view filing)7:05 PM ETAug 182 daysZalevsky JonathanChief R&D OfficerSSale−186$71.98−$13.4K−1.9%9.57K after
Aug 20, 2026 (view filing)7:03 PM ETAug 182 daysRobin Howard WPresident & CEOSSale−418$71.98−$30.1K−0.8%54.6K after
Jul 2, 2026 (view filing)7:06 PM ETJun 302 daysZalevsky JonathanChief R&D OfficerSSale−5.68K$70.00−$397.7K−36.8%9.76K after10b5-1
Jun 18, 2026 (view filing)Jun 16-172 daysRobin Howard WPresident & CEOSSale−20.0K$60.75−$1.22M−26.7%55.0K after4 lots10b5-1
Jun 17, 2026 (view filing)Jun 152 daysZalevsky JonathanChief R&D OfficerSSale−5.54K$60.71−$336.2K−26.4%15.4K after10b5-1
May 21, 2026 (view filing)May 192 daysZalevsky JonathanChief R&D OfficerSSale−199$65.51−$13.0K−0.9%21.0K after
May 21, 2026 (view filing)May 192 daysRobin Howard WPresident & CEOSSale−444$65.51−$29.1K−0.6%75.0K after
Feb 20, 2026 (view filing)Feb 182 daysZalevsky JonathanChief R&D OfficerSSale−180$73.00−$13.1K−0.8%21.2K after

Top 10 13F holders, Q3 2026

See all 242 holders

The largest institutional positions in Nektar Therapeutics at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding NKTR in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC5,121,441$310.1M0.01%+53,521+1.1%Added
Two Seas Capital LP3,345,978$202.6M8.07%+253,744+8.2%Added
BlackRock, Inc.2,871,463$173.9M0.00%−70,388−2.4%Reduced
BVF Inc2,134,007$129.2M4.25%−257,068−10.8%Reduced
State Street Corp1,772,302$107.3M0.00%+862,623+94.8%Added
Vanguard Capital Management LLC1,501,608$90.9M0.00%+4,759+0.3%Added
Two Sigma Investments, LP1,208,270$73.2M0.05%+6,266+0.5%Added
Geode Capital Management, LLC891,927$54.0M0.00%+10,621+1.2%Added
Morgan Stanley830,210$50.3M0.00%−106,350−11.4%Reduced
Prosight Management, LP785,000$47.5M9.22%−25,000−3.1%Reduced

Holders of 5% or more of NKTR

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nektar Therapeutics.

Largest holders of NKTR from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A15.00%4.30M shares+3.90 ppfrom 11.10%Feb 8, 20215 filingsMay 6, 2026SEC
Two Seas Capital LP13G/A9.80%3.35M shares+0.70 ppfrom 9.10%Apr 17, 20263 filingsSep 28, 2026SEC
BlackRock, Inc.13G7.80%2.64M shares+6.20 ppfrom 1.60%Jul 18, 20252 filingsJul 29, 2026SEC
Biotechnology Value Fund L P13G/A7.10%2.39M shares−2.70 ppfrom 9.80%Jul 9, 20253 filingsAug 14, 2026SEC
BlackRock, Inc.13G/A6.70%12.5M shares–Oct 22, 20243 filingsApr 17, 2025SEC